NeilEttingerMD

Pulmonology • Chesterfield, MO

Critical Care Medicine, Pleural Disease

Physician

Join to view full profile

Dr. Ettinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ettinger's full profile

Already have an account?

Office
222 S Woods Mill Rd
Ste 310N
Chesterfield, MO 63017
Phone+1 314-576-6700

Fax+1 314-576-6520

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1990
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1983 - 1986
Washington University in St. Louis School of MedicineClass of 1983

Certifications & Licensure

FL State Medical License 1995 - 2026
MO State Medical License 1985 - 2025
IL State Medical License 1993 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Top MD Consumers Checkbook

Clinical Trials

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2006 May 01
Completed
Phase 4
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
Completed
Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
Terminated
Phase 3
Early Diagnosis of Pulmonary Nodules Start of enrollment: 2012 Oct 01
Completed
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

18 citations
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Sympo...
Ganesh Raghu, Marya Ghazipura, Thomas R Fleming, Kerri I Aronson, Jürgen Behr
American Journal of Respiratory and Critical Care Medicine. 2024-03-15
23 citations
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
Christopher S. King, Kevin R. Flaherty, Marilyn K. Glassberg, Lisa Lancaster, Ganesh Raghu
Annals of the American Thoracic Society. 2021-10-22
47 citations
A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis.
Steven D. Nathan, Kevin R. Flaherty, Marilyn K. Glassberg, Ganesh Raghu, Jeffrey J. Swigris
Chest. 2020-08-01